Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast And Gastric Cancers Resistant to Trastuzumab Emtansine.

Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P, Joensuu H, Barok M.

Mol Cancer Ther. 2019 Jul 10. pii: molcanther.0207.2019. doi: 10.1158/1535-7163.MCT-19-0207. [Epub ahead of print]

PMID:
31292166
2.

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.

Barok M, Puhka M, Vereb G, Szollosi J, Isola J, Joensuu H.

BMC Cancer. 2018 May 2;18(1):504. doi: 10.1186/s12885-018-4418-2.

3.

Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer.

Luhtala S, Staff S, Barok M, Tanner M, Isola J.

Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):212-219. doi: 10.1097/PAI.0000000000000406.

PMID:
27389555
4.

Trastuzumab emtansine: mechanisms of action and drug resistance.

Barok M, Joensuu H, Isola J.

Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621. Review.

5.

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.

Barok M, Tanner M, Köninki K, Isola J.

Breast Cancer Res. 2011 Apr 21;13(2):R46. doi: 10.1186/bcr2868.

6.

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

Barok M, Tanner M, Köninki K, Isola J.

Cancer Lett. 2011 Jul 28;306(2):171-9. doi: 10.1016/j.canlet.2011.03.002. Epub 2011 Apr 1.

PMID:
21458915
7.

Steps in metastasis research: analyzing, collecting, and culturing circulating tumor cells.

Barok M, Szollosi J.

Cytometry A. 2011 Feb;79(2):93-4. doi: 10.1002/cyto.a.21025. No abstract available.

8.

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.

Köninki K, Barok M, Tanner M, Staff S, Pitkänen J, Hemmilä P, Ilvesaro J, Isola J.

Cancer Lett. 2010 Aug 28;294(2):211-9. doi: 10.1016/j.canlet.2010.02.002. Epub 2010 Mar 2.

PMID:
20193978
9.

Characterization of a novel, trastuzumab resistant human breast cancer cell line.

Barok M, Balazs M, Lazar V, Rakosy Z, Toth E, Treszl A, Vereb G, Colbern GT, Park JW, Szollosi J.

Front Biosci (Elite Ed). 2010 Jan 1;2:627-40.

PMID:
20036907
10.

Die hard: are cancer stem cells the Bruce Willises of tumor biology?

Fábián A, Barok M, Vereb G, Szöllosi J.

Cytometry A. 2009 Jan;75(1):67-74. doi: 10.1002/cyto.a.20690. Review.

11.

EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44.

Pályi-Krekk Z, Barok M, Kovács T, Saya H, Nagano O, Szöllosi J, Nagy P.

Cancer Lett. 2008 May 18;263(2):231-42. doi: 10.1016/j.canlet.2008.01.014. Epub 2008 Feb 13.

PMID:
18276068
12.

ErbB-directed immunotherapy: antibodies in current practice and promising new agents.

Friedländer E, Barok M, Szöllosi J, Vereb G.

Immunol Lett. 2008 Mar 15;116(2):126-40. doi: 10.1016/j.imlet.2007.12.001. Epub 2007 Dec 26. Review. Erratum in: Immunol Lett. 2009 May 14;124(1):55-6.

PMID:
18201769
13.

Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.

Barok M, Balázs M, Nagy P, Rákosy Z, Treszl A, Tóth E, Juhász I, Park JW, Isola J, Vereb G, Szöllosi J.

Cancer Lett. 2008 Feb 18;260(1-2):198-208. Epub 2007 Dec 21.

PMID:
18096313
14.

Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.

Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllosi J, Nagy P.

Eur J Cancer. 2007 Nov;43(16):2423-33.

PMID:
17911008
15.

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.

Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllösi J.

Mol Cancer Ther. 2007 Jul;6(7):2065-72.

16.

EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis.

Rákosy Z, Vízkeleti L, Ecsedi S, Vokó Z, Bégány A, Barok M, Krekk Z, Gallai M, Szentirmay Z, Adány R, Balázs M.

Int J Cancer. 2007 Oct 15;121(8):1729-37.

Supplemental Content

Support Center